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Jervell and Lange-Nielsen syndrome (JLNS) 
is an ion channel-caused cardioauditory syndrome 
characterized by a congenital neurosensorial bi-
lateral deafness and a long QT interval. JLNS is 
inherited in an autosomal recessive manner and is 
caused by mutations in the KCNQ1 gene (potassium 
voltage-gated channel subfamily Q member 1) [1].
The proband was an 8-year-old male who pre-
sented with a family history of sudden death and 
congenital sensorineural deafness. Initial clinical 
evaluation of the proband showed a mild cranial 
trauma and minor occipital subgaleal hematoma. 
No significant cardiovascular findings were noted, 
but electrocardiography (ECG) analysis (ECG Edan 
SE-1200, USA) revealed a prolonged QT/QTc in 
the lead II (420/460 ms) (Fig. 1A, left). Despite the 
use of beta-blocker (2 mg/kg/day) therapy at home, 
the patient experienced a syncopal event related 
to emotional stress. 
Viskin test [2] was performed, and the results 
did not support an long QT syndrome (LQTS)-
-related orthostatic event (baseline QTc 465 ms 
in resting phase, QTc MHR of 492 ms, and QTc 
recovery of 444 ms). An adrenaline test [3] was 
performed at doses of 0.025 µg/kg/min, enabling 
a QTc of 550 ms without an arrhytmic event 
(Fig. 1A, right), and met LQTS electrocardiograph-
ic criteria. QTc 686 ms was observed under stress 
after placement of the implantable cardioverter-
defibrillator (ICD) and beta-blockers. At follow up, 
the patient was ventricular arrhytmia-free or shock 
therapy during the 4 years after ICD implantation. 
After clinical and cardiac electrophysiology, the 
patient was diagnosed with JLNS.
Molecular genetic analysis was performed by 
next generation sequencing in the proband, and 
4 family members were clinically affected (Fig. 1B). 
Electrocardiographic assessment of the mother and 
maternal grandparents revealed borderline QTc 
values. The electrocardiographies were measured 
by the Bazett formula. Only the index case was 
genotyped and the family members declined to 
do genetic testing until there was more evidence 
that genetic testing had to be recommended by 
a genetic counselor.
High throughput DNA sequencing was per-
formed using an Ion Torrent Personal Genome 
Machine to target and sequence 87 candidate 
genes linked with inhereted cardiac arrhythmia 
syndromes. These candidate genes were selected 
based on their relative expression in the human 
heart and their ability to modulate ion channel 
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Figure 1. A. Clinical electrocardiography analysis; Left. Electrocardiography during the first syncopal event with 
QTc of 460 ms by Bazett formula; Right. Electrocardiography during the adrenaline test with QTc 550 ms by Bazett 
formula at the second syncopal event; B. Patient’s pedigree; I (1). Maternal grandfather; I (2). Maternal grandmother; 
I (3). Maternal granduncle; I (4). Maternal grandaunt; II (1). Patient’s father; II (2). Patient’s mother; II (3). Maternal 
uncle; III (1). Patient; III (2). Patient’s brother; III (3). Patient’s cousin; III (4). Patient’s cousin; SD — sudden death; 
C. Schematic molecular genetics and localization of KCNQ1 mutation and AKAP9 novel genetic variant. Long QT syn-
drome, like severe Jervell and Lange-Nielsen syndrome, is associated with sudden cardiac death syndromes. KCNQ1 
mutation and AKAP9 variant and proteins location and possible interaction in the C-Terminus in the plasma membrane 
that maybe expressed in the brain, muscle and heart tissues; D. Molecular genetics of novel genetic variants (AKAP9; 
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expression and function: ABCC8, ABCC9, ACTC1, 
ACTN2, AGTR1, AKAP9, ANK2, CACNA1C, 
CACNA2D1, CACNA2D2, CACNB1, CACNB2, 
CACNB3, CACNB4, CACNG4, CACNG5, CAC-
NG6, CALM1, CALM2, CASQ2, CAV1, CAV2, 
CAV3, DSG2, DSP, DPP6, DPP7, DPP8, DPP9, 
DPP10, FGF12, FGF13, GATAD1, GJA5, GLA, 
GPD1L, HCN2, HCN4, HEY2, IRX3, IRX4, IRX5, 
JPH2, KCNA4, KCNA5, KCNN1, KCNN2, KCNN3, 
KCNK1, KCNK2, KCNK3, KCND3, KCNE1, 
KCNE2, KCNE3, KCNE4, KCNE5, KCNH2, KC-
NIP2, KCNJ2, KCNJ8, KCNJ9, KCNJ10, KCNQ1, 
KCNQ2, PKP2, PRKAG2, PXDNL, RYR2, SCN1A, 
SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SC-
N10A, SCN1B, SCN2B, SCN3B, SCN4B, SEMA3C, 
SNTA1, SUR1A, SUR2A, TBX5, TRPM4, TTN. All 
genetic variants uncovered were confirmed using 
the gold standard Sanger sequencing. Polymerase 
chain reaction (PCR) products were purified with 
a commercial enzyme (ExoSAP- IT, USB, Cleve-
land, OH) and directly sequenced from both direc-
tions using BigDye Terminator v3.1 chemistry on 
an Applied Biosystems 3730DNA Analyzer (Life 
Technologies, Carlsbad, CA). 
After signal processing and basecalling, the 
Ion Torrent Suite software was used to map the 
sequencing reads to the DNA reference sequence 
(hg19) and identify variants through the Variant 
Caller plugin as well as the Ion Reporter analysis 
tool. Ion Reporter compares all variations identified 
against NCBI’s dbSNP to rule out common SNPs, 
as well as the 1000 Genomes Project and Exome 
Sequencing Project to get published frequencies. 
All variations uncovered were probed in 200–400 
healthy ethnically matched controls. Genetic 
variant under 0.05% minor allele frequency were 
considered mutations and above 0.05–2.5% rare 
variants, following American College of Medical 
Genetics (ACMG) recommendations [4]. All vari-
ants were analyzed using several pathogenicity in 
silico prediction tools such as PolyPhen-2, SIFT 
and Grantham.
Three novel heterozygous exonic were identified, 
likely benign variants to be associated in this index 
patient diagnosed with JLNS, AKAP9(p.Ile2392Arg); 
JPH2(p.Gly52Ser); SCN10A(p.Thr440Ser), and one 
moderate pathogenic rare variant SCN7A(p.Tyr-
562Cys) [4]. Two mutations in KCNQ1 were already 
discovered in the patient (p.Gln356_Gln357del and 
p.Ala300Thr) [5, 6]. According to available research, 
this is the first evidence of polygenic variants in 
a confirmed case of clinically severe JLNS. In this 
case, polygenic variants may be explained by con-
sanguineous relations among the patient’s relatives, 
consistent with local traditions still prevalent in small 
populations. Surprisingly, the ECG abnormalities 
manifested only in the index patient who carried the 
mutations and genetic variants in five different genes 
with a very interesting double deletion in KCNQ1 
with a close physical protein–protein interaction with 
the AKAP9 gene (Fig. 1C). Based on the clinical and 
ECGs phenotype associated with LQTS one of the 
main culprit genes could be the doble mutations in 
the KCNQ1 gene and genetic variant in AKAP9 to 
induce QT prolongation. It has been described that 
multiple genes identified could play together a role in 
the development of the LQTS phenotype at the same 
time or to be associated with any cardiac arrhythmia 
syndrome [6].
Genetic variants found in the case reported 
have been rarely associated with disease in 
previous reports. The observed variant JPH2 
(p.Gly505Ser) has been related to hypertrophic 
cardiomyopathy [7], whereas the relationship of the 
observed variants in SCN10A and SCN7A genes 
have not been previously characterized for a JLNS-
-related phenotype. In another context, almost 30 
pathogenic genetic variants of KCNQ1 gene have 
been associated with JLNS [8]; meanwhile, both 
deletion and duplication of one or more exons of 
KCNQ1 are known to cause LQTS [9]. In the pre-
sent study the two mutations in KCNQ1 have been 
related with LQTS and sudden unexpected death 
syndromes [5, 6]. KCNQ1 also has been found to 
co-interact with AKAP9 by reducing the IKs chan-
nels, and it has been associated with prolongation 
of the QT interval as a potential marker for long 
QT type 1-modified effects [10]. 
Localization of the KCNQ1 mutations and 
AKAP9 genetic variant in the proband are shown 
in Figure 1D. The hypothesis herein, is based on 
the possible loss-of-function in the potassium in 
comparison to WT channels when predicted by in 
silico prediction [11]; however, in vitro functional 
studies may need it to clarify the ionic mechanisms. 
These potential pathophysiological deficiencies may 
alter the phenotypic manifestation of LQTS as well 
as the responsiveness to pharmacological therapies.
In summary, four novel genetic variants were 
found [AKAP9(p.Ile2392Arg); JPH2(p.Gly52Ser); 
SCN10A(p.Thr440Ser) and SCN7A(p.Tyr562Cys)] 
and two known mutations in KCNQ1 in a patient 
with ventricular arrhythmias with similarities to 
long QT type 1-modified effects. Moreover, none 
of these variants has been linked to either LQTS 
or other sudden cardiac death syndromes. 
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